Status of the receptors | ER–/PR– | ER+/PR– | ER–/PR+ | ER+/ PR+ | |||||
Exposure metrics | n controls | n cases | OR* 95% CI | n cases | OR* 95% CI | n cases | OR* 95% CI | n cases | OR*, 95% CI |
Exposed to organic solvents | |||||||||
Never | 2093 | 449 | 1.0 | 301 | 1.0 | 98 | 1.0 | 778 | 1.0 |
Ever | 409 | 120 | 1.40 (1.1 to 1.8) | 71 | 1.27 (0.95 to 1.7) | 20 | 1.11 (0.7 to 1.8) | 137 | 0.97 (0.8 to 1.2) |
p Heterogeneity ¶ | 0.56 | 0.40 | 0.008 | ||||||
Duration of exposure (years)† | |||||||||
>0–5 | 124 | 37 | 1.45 (0.98 to 2.1) | 16 | 1.06 (0.6 to 1.8) | 7 | 1.22 (0.5 to 2.7) | 41 | 0.99 (0.7 to 1.4) |
>5–10 | 72 | 18 | 1.17 (0.7 to 2.0) | 17 | 1.71 (1.0 to 3.1) | 3 | 0.90 (0.3 to 2.9) | 29 | 1.14 (0.7 to 1.8) |
>10 | 213 | 65 | 1.46 (1.1 to 2.0) | 38 | 1.23 (0.8 to 1.8) | 10 | 1.14 (0.6 to 2.2) | 67 | 0.90 (0.7 to 1.2) |
p Trend§ | 0.82 | 0.76 | 0.63 | 0.65 | |||||
p Heterogeneity of trends¶ | 0.91 | 0.58 | 0.58 | ||||||
Crude intensity (quantity used in l/mo)† | |||||||||
≥1–10 | 313 | 95 | 1.43 (1.1 to 1.8) | 54 | 1.22 (0.9 to 1.7) | 17 | 1.20 (0.7 to 2.0) | 111 | 0.99 (0.8 to 1.3) |
>10–100 | 77 | 24 | 1.55 (0.96 to 2.5) | 15 | 1.58 (0.9 to 2.8) | 3 | 0.99 (0.3 to 3.2) | 25 | 1.04 (0.6 to 1.7) |
>100 | 19 | 1 | 0.31 (0.04 to 2.3) | 2 | 1.02 (0.2 to 4.5) | 0 | 1 | 0.21 (0.03 to 1.6) | |
p Trend§ | 0.33 | 0.97 | 0.43 | 0.39 | |||||
p Heterogeneity of trends¶ | 0.47 | 0.68 | 0.92 | ||||||
Crude average frequency (h/wk)† | |||||||||
≥1–<2 | 20 | 9 | 2.20 (0.98 to 4.9) | 5 | 1.70 (0.6 to 4.7) | 2 | 2.62 (0.6 to 11.3) | 14 | 2.05 (1.0 to 4.2) |
≥2–≤10 | 110 | 35 | 1.40 (0.9 to 2.1) | 15 | 0.79 (0.4 to 1.4) | 8 | 1.59 (0.7 to 3.4) | 49 | 1.06 (0.7 to 1.5) |
>10–<20 | 185 | 46 | 1.23 (0.9 to 1.7) | 39 | 1.64 (1.1 to 2.4) | 6 | 0.74 (0.3 to 1.7) | 47 | 0.76 (0.5 to 1.1) |
≥20 | 94 | 30 | 1.59 (1.0 to 2.5) | 12 | 1.23 (0.6 to 2.3) | 4 | 0.98 (0.3 to 2.8) | 27 | 1.00 (0.6 to 1.6) |
p Trend§ | 0.59 | 0.24 | 0.14 | 0.10 | |||||
p Heterogeneity of trends¶ | 0.18 | 0.24 | 0.40 | ||||||
Average latency (years)† | |||||||||
0–15 | 34 | 15 | 1.98 (1.0 to 3.7) | 4 | 1.39 (0.5 to 4.0) | 2 | 1.05 (0.2 to 4.5) | 16 | 1.40 (0.7 to 2.6) |
>15 | 375 | 105 | 1.35 (1.1 to 1.7) | 67 | 1.26 (0.9 to 1.7) | 18 | 1.13 (0.7 to 1.9) | 121 | 0.94 (0.7 to 1.2) |
p Trend§ | 0.26 | 0.94 | 0.39 | 0.19 | |||||
p Heterogeneity of trends¶ | 0.49 | 0.73 | 0.91 | ||||||
Cumulative exposure (h*l*years/wk*mo)†,‡ | |||||||||
>0–39 | 206 | 61 | 1.42 (1.0 to 1.9) | 29 | 1.08 (0.7 to 1.6) | 9 | 0.95 (0.5 to 1.9) | 75 | 1.05 (0.8 to 1.4) |
>39 | 203 | 59 | 1.39 (1.0 to 1.9) | 42 | 1.44 (1.0 to 2.1) | 11 | 1.30 (0.7 to 2.5) | 62 | 0.88 (0.7 to 1.2) |
p Trend§ | 0.74 | 0.30 | 0.85 | 0.38 | |||||
p Heterogeneity of trends¶ | 0.26 | 0.75 | 0.67 | ||||||
Highest intensity*frequency (l*h/mo*wk)†,‡ | |||||||||
I level | 298 | 92 | 1.46 (1.1 to 1.9) | 53 | 1.25 (0.9 to 1.7) | 12 | 0.90 (0.5 to 1.7) | 107 | 1.01 (0.8 to 1.3) |
II level | 111 | 28 | 1.25 (0.8 to 1.9) | 18 | 1.36 (0.8 to 2.3) | 8 | 1.77 (0.8 to 3.7) | 30 | 0.86 (0.6 to 1.3) |
p Trend§ | 0.51 | 0.95 | 0.23 | 0.67 | |||||
p Heterogeneity of trends¶ | 0.61 | 0.15 | 0.84 | ||||||
Crude average probability† | |||||||||
≥1–<10% | 128 | 37 | 1.31 (0.9 to 1.9) | 22 | 1.23 (0.6 to 2.0) | 7 | 1.20 (0.5 to 2.7) | 47 | 1.06 (0.7 to 1.5) |
≥10–<50% | 134 | 39 | 1.40 (0.96 to 2.0) | 24 | 1.20 (0.8 to 1.9) | 5 | 0.86 (0.3 to 2.2) | 49 | 0.98 (0.7 to 1.4) |
≥50–<90% | 113 | 27 | 1.21 (0.8 to 1.9) | 23 | 1.60 (0.99 to 2.6) | 8 | 1.64 (0.8 to 3.5) | 31 | 0.83 (0.5 to 1.3) |
≥90% | 34 | 17 | 2.44 (1.3 to 4.5) | 2 | 0.54 (0.1 to 2.3) | 0 | 10 | 0.99 (0.5 to 2.0) | |
p Trend§ | 0.43 | 0.77 | 0.56 | 0.47 | |||||
p Heterogeneity of trends¶ | 0.80 | 0.38 | 0.22 |
↵* Adjusted for age, study site, education, body mass index (BMI), age at menarche, menopausal status, age at menopause (in postmenopausal women), number of full-term births, age at first full-term birth, breastfeeding and family history of breast cancer.
↵† Never exposed to organic solvents used as referent.
↵‡ For definitions see e-table I.
↵§ p For trend in ever exposed to organic solvents.
↵¶ Compared with ER–/PR– cases.